Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed plus erlotinib as salvage therapy in metastatic biliary tract cancer after gemcitabine failure
KCT0005787Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed, erlotinib in biliary cancer, sponsored by Samsung Medical Center. Started Jun 2021; status: completed.
02
Drugs
pemetrexederlotinib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on KCT0005787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005787.